Opioid Use Disorder study: Sublingual Buprenorphine
Official title Assessing Optimal XRB Initiation Points in Jail
ClinicalTrials.gov ID: NCT06051890
What this study is testing
What is Extended-Release Buprenorphine (XRB)?
an investigational monthly injectable medicine being studied as a potential treatment for opioid use disorder is designed to slowly release buprenorphine over 28 days, providing continuous activation of opioid receptors to help reduce cravings and withdrawal symptoms
Also referred to as Sublocade.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study compares two ways of giving medication for opioid use disorder: starting extended‑release buprenorphine right when a person enters jail versus continuing the usual sublingual buprenorphine. It looks at how many people have the medication in their system when they leave jail, how many keep treatment after release, and whether the medication is misused.
- Who it's for
- Adults who are already prescribed sublingual buprenorphine and are entering Middlesex County House of Corrections as pre‑trial detainees.
- What's involved
- Participants are randomly assigned to either start extended‑release buprenorphine at admission or stay on their current sublingual medication. All receive naloxone. The study follows them for 3 years, tracking medication use, treatment continuation, and any diversion incidents.
- Time commitment
- The trial lasts 3 years, with regular check‑ins and monitoring throughout the participants’ time in jail and after release.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults, men only
You may be able to join if
- Incarcerated men able to provide written informed consent in English.\
- Unsentenced.
- Entering the facility with a prescription for SLB and receiving SLB for at least the previous 3 days.
- Minimum anticipated jail stay is 4 days.
- Willing to accept being assigned by chance to the experimental condition (i.e., transitioning to XRB while incarcerated).
You likely can't join if
- Sentenced.
- Allergy, hypersensitivity or medical contraindication to either medication.
- Chronic pain requiring opioid pain management or other contraindicated medications.
The study team makes the final eligibility decision.
Where it is enrolling
- Boston, Massachusetts, United States
- Springfield, Massachusetts, United States
- New Brunswick, New Jersey, United States
- New York, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Boston, Massachusetts, United States; Springfield, Massachusetts, United States; New Brunswick, New Jersey, United States; New York, New York, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.